Janux Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $10.0 | $10.6 | $8.1 | $8.6 | $3.6 |
| Operating income | -$157.7 | -$98.8 | -$73.0 | -$67.1 | -$32.9 |
| Net income | -$113.6 | -$69.0 | -$58.3 | -$63.1 | -$32.7 |
| Cash Flow Statement | |||||
| Free cash flow | -$83.3 | -$44.2 | -$52.4 | -$49.4 | -$18.5 |
Shares outstanding 61.0M · Free float 41.1%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.